Oxford, UK, October 2026. OGT, a leading global provider of genomic research and diagnostic solutions, today announced the launch of the SureSeq myPanel™ Myeloid Fusion MRD Panel, the first-to-market dedicated fusion MRD next-generation sequencing (NGS) panel for acute myeloid leukemia (AML). This panel is now available publicly for customers to purchase and implement in their own workflows.
Genomic AML workflows traditionally cover only part of the genomic landscape, with important fusion events being potentially undetected. This new myPanel, a custom SureSeq™ NGS panel, developed in collaboration with Roswell Park Comprehensive Cancer Center using the myPanel custom service, enables the detection of AML-associated fusion events and identifies MECOM expression levels at MRD-level sensitivity, generating broader fusion insights for AML sample cohorts in a single assay.
“Important fusion signals are difficult to identify when workflows depend on multiple assays or have insufficient sensitivity,” said Adrian Smith, CEO at OGT. “We’re proud to launch the first dedicated Fusion MRD NGS panel for AML that empowers laboratories with a focused tool to detect, analyze and track fusion events at MRD-level sensitivity. Used independently or alongside our SureSeq Myeloid MRD Plus NGS Panel, this panel has the potential to capture a wide range of disease-associated fusion events at MRD-levels of sensitivity that may otherwise be missed, and thus provides a broader genomic profile of AML samples for deeper insights.”
In an initial study of clinical research samples, carried out at Roswell Park Comprehensive Cancer Center, the SureSeq myPanel Fusion MRD NGS workflow was shown to detect key disease-associated fusion events, including BCR::ABL1 and PML::RARA in serial dilutions as low as 1% tumor cells.
“The addition of RNA fusion detection represents an important opportunity to broaden the reach of molecular MRD assessment to the approximately 20–25% of AML cases associated with fusion-driven disease," said Dr Sean Glenn, Director of the Advanced Molecular Diagnostics Laboratory, Roswell Park Comprehensive Cancer Center. “By providing molecular markers of residual leukaemia that can be monitored over time, fusion transcripts can support residual disease assessment, including in samples that lack an informative DNA mutation.”
As part of the end-to-end SureSeq NGS workflow, OGT’s complimentary NGS analysis software, Interpret, allows laboratories to analyze, track and visualize variants, including fusion events, across multiple timepoints within a single software environment. Available through cloud and local installation options, and with options for integration of 3rd party tools including QIAGEN Clinical Insight (QCI®) Interpret, clinical researchers can easily follow AML disease dynamics and generate key genomic insights from their NGS data.
The launch reflects OGT’s commitment to creating genomic solutions for scientists, by scientists. The SureSeq myPanel Myeloid Fusion MRD Panel can be used as a standalone assay for fusion event detection or used alongside the SureSeq Myeloid MRD Plus NGS Panel for broader MRD characterization. Together, these panels support MRD-level detection of SNVs, indels, ITDs and fusion events in AML samples, enabling researchers to expand the range of detectable variants without relying on multiple single-analyte assays.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 30 years at the forefront of genetic endeavor, but also by working closely with scientists to understand their unique challenges, and to customize its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell®:Some products may not be available in your region.
Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey."* Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
* "Healthcare journey" is a trademark of Sysmex Corporation, registered in Japan.
Enables ultra-low variant detection across a range of key MRD targets in AML, including very large FLT3-ITDs.
Read
Delivering reduced hands-on time, more consistent results and higher sample throughput
Read
Helping high-throughput laboratories increase multiplexing capacity and maximize sequencing throughput without changing established workflows
Read
Visit International site
Visit USA site